564 related articles for article (PubMed ID: 33023239)
21. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes?
Bangia N; Ferrone S
Immunol Invest; 2006; 35(3-4):485-503. PubMed ID: 16916763
[No Abstract] [Full Text] [Related]
22. The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells.
Giorda E; Sibilio L; Martayan A; Moretti S; Venturo I; Mottolese M; Ferrara GB; Cappellacci S; Eibenschutz L; Catricalà C; Grammatico P; Giacomini P
Cancer Res; 2003 Jul; 63(14):4119-27. PubMed ID: 12874016
[TBL] [Abstract][Full Text] [Related]
23. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.
Facoetti A; Nano R; Zelini P; Morbini P; Benericetti E; Ceroni M; Campoli M; Ferrone S
Clin Cancer Res; 2005 Dec; 11(23):8304-11. PubMed ID: 16322289
[TBL] [Abstract][Full Text] [Related]
24. Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review.
Sadagopan A; Michelakos T; Boyiadzis G; Ferrone C; Ferrone S
JAMA Oncol; 2022 Mar; 8(3):462-473. PubMed ID: 34940799
[TBL] [Abstract][Full Text] [Related]
25. Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells.
Concha-Benavente F; Srivastava R; Ferrone S; Ferris RL
Oral Oncol; 2016 Jul; 58():52-8. PubMed ID: 27264839
[TBL] [Abstract][Full Text] [Related]
26. Human leukocyte antigen and tumor immunotherapy (Review).
Liu DH; Mou FF; An M; Xia P
Int J Oncol; 2023 Jun; 62(6):. PubMed ID: 37114561
[TBL] [Abstract][Full Text] [Related]
27. Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy.
Vigneron N; Abi Habib J; Van den Eynde BJ
Trends Cancer; 2017 Oct; 3(10):726-741. PubMed ID: 28958390
[TBL] [Abstract][Full Text] [Related]
28. Novel insights into the molecular mechanisms of HLA class I abnormalities.
Seliger B
Cancer Immunol Immunother; 2012 Feb; 61(2):249-254. PubMed ID: 22120755
[TBL] [Abstract][Full Text] [Related]
29. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
30. WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?
Mehling M; Simon P; Mittelbronn M; Meyermann R; Ferrone S; Weller M; Wiendl H
Acta Neuropathol; 2007 Aug; 114(2):111-9. PubMed ID: 17541610
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?
Atkins D; Ferrone S; Schmahl GE; Störkel S; Seliger B
J Urol; 2004 Feb; 171(2 Pt 1):885-9. PubMed ID: 14713847
[TBL] [Abstract][Full Text] [Related]
32. HLA class I defects in malignant lesions: what have we learned?
Chang CC; Campoli M; Ferrone S
Keio J Med; 2003 Dec; 52(4):220-9. PubMed ID: 14748474
[TBL] [Abstract][Full Text] [Related]
33. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma.
Raffaghello L; Nozza P; Morandi F; Camoriano M; Wang X; Garrè ML; Cama A; Basso G; Ferrone S; Gambini C; Pistoia V
Cancer Res; 2007 Jun; 67(11):5471-8. PubMed ID: 17545629
[TBL] [Abstract][Full Text] [Related]
34. Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
[TBL] [Abstract][Full Text] [Related]
35. Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
de Charette M; Marabelle A; Houot R
Eur J Cancer; 2016 Nov; 68():134-147. PubMed ID: 27755997
[TBL] [Abstract][Full Text] [Related]
36. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer.
Ferris RL; Whiteside TL; Ferrone S
Clin Cancer Res; 2006 Jul; 12(13):3890-5. PubMed ID: 16818683
[TBL] [Abstract][Full Text] [Related]
37. HLA-G: A New Immune Checkpoint in Cancer?
Krijgsman D; Roelands J; Hendrickx W; Bedognetti D; Kuppen PJK
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630545
[TBL] [Abstract][Full Text] [Related]
38. Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.
Al-Sukaini A; Hornicek FJ; Peacock ZS; Kaban LB; Ferrone S; Schwab JH
Clin Orthop Relat Res; 2017 Dec; 475(12):3071-3081. PubMed ID: 28725958
[TBL] [Abstract][Full Text] [Related]
39. The role of surface HLA-A,B,C molecules in tumour immunity.
Möller P; Hämmerling GJ
Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges.
Lin A; Yan WH
Front Immunol; 2018; 9():2164. PubMed ID: 30319626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
